WallStSmart

Evolus Inc (EOLS)vsUnited Therapeutics Corporation (UTHR)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

United Therapeutics Corporation generates 950% more annual revenue ($3.17B vs $301.79M). UTHR leads profitability with a 40.6% profit margin vs -14.4%. UTHR earns a higher WallStSmart Score of 57/100 (C).

EOLS

Avoid

30

out of 100

Grade: F

Growth: 6.7Profit: 2.0Value: 6.7Quality: 6.0
Piotroski: 2/9Altman Z: -2.97

UTHR

Buy

57

out of 100

Grade: C

Growth: 4.0Profit: 9.0Value: 5.3Quality: 7.8
Piotroski: 5/9Altman Z: 8.56
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

EOLSUndervalued (+71.0%)

Margin of Safety

+71.0%

Fair Value

$14.83

Current Price

$6.67

$8.16 discount

UndervaluedFair: $14.83Overvalued
UTHRUndervalued (+2.5%)

Margin of Safety

+2.5%

Fair Value

$487.82

Current Price

$549.87

$62.05 discount

UndervaluedFair: $487.82Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

EOLS1 strengths · Avg: 10.0/10
Debt/EquityHealth
-5.7310/10

Conservative balance sheet, low leverage

UTHR4 strengths · Avg: 9.8/10
Profit MarginProfitability
40.6%10/10

Keeps 41 of every $100 in revenue as profit

Operating MarginProfitability
41.7%10/10

Strong operational efficiency at 41.7%

Altman Z-ScoreHealth
8.5610/10

Safe zone — low bankruptcy risk

Return on EquityProfitability
21.8%9/10

Every $100 of equity generates 22 in profit

Areas to Watch

EOLS4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$439.25M3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

Return on EquityProfitability
-18730.0%2/10

ROE of -18730.0% — below average capital efficiency

UTHR3 concerns · Avg: 2.7/10
PEG RatioValuation
2.244/10

Expensive relative to growth rate

Revenue GrowthGrowth
-1.6%2/10

Revenue declined 1.6%

EPS GrowthGrowth
-12.2%2/10

Earnings declined 12.2%

Comparative Analysis Report

WallStSmart Research

Bull Case : EOLS

The strongest argument for EOLS centers on Debt/Equity.

Bull Case : UTHR

The strongest argument for UTHR centers on Profit Margin, Operating Margin, Altman Z-Score. Profitability is solid with margins at 40.6% and operating margin at 41.7%.

Bear Case : EOLS

The primary concerns for EOLS are EPS Growth, Market Cap, Piotroski F-Score.

Bear Case : UTHR

The primary concerns for UTHR are PEG Ratio, Revenue Growth, EPS Growth.

Key Dynamics to Monitor

EOLS profiles as a turnaround stock while UTHR is a declining play — different risk/reward profiles.

EOLS carries more volatility with a beta of 1.33 — expect wider price swings.

EOLS is growing revenue faster at 6.7% — sustainability is the question.

UTHR generates stronger free cash flow (363M), providing more financial flexibility.

Bottom Line

UTHR scores higher overall (57/100 vs 30/100), backed by strong 40.6% margins. EOLS offers better value entry with a 71.0% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Evolus Inc

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Evolus, Inc., a high-performance beauty company, provides aesthetic medical products for physicians and their patients in the United States. The company is headquartered in Newport Beach, California.

United Therapeutics Corporation

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

United Therapeutics Corporation, a biotechnology company, is dedicated to the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company is headquartered in Silver Spring, Maryland.

Visit Website →

Want to dig deeper into these stocks?